MSB ....

All,

A reminder that there will be an update on Mesoblast’s Phase 2 trial in diabetic nephropathy in a call to be conducted at 0900 today (AEST) / 7pm today (EDT) / midnight today (BST).

Please see the attached poster -Mesenchymal Precursor Cell Therapy for Diabetic Nephropathy: A Phase 2 Randomized Controlled Trial –presented at the 75th late-breaking scientific sessions of the American Diabetes Association currently being held in Boston.


Joining Mesoblast Chief Executive Silviu Itescu as speakers are:

· The trial's lead investigator, Associate Professor David Packham, Department of Medicine, University of Melbourne, and Director of the Melbourne Renal Research Group

· Professor Paul Zimmet,Adjunct Professor at the Graduate School of Public Health of the University of Pittsburgh, Pennsylvania, and Head of WHO Collaborating Centre for the Epidemiology of Diabetes Mellitus, Director Emeritus and Director of International Research of the Baker IDI Heart and Diabetes Institute, Foundation Director of the International Diabetes Institute, and Hon. Professor at Monash and Deakin Universities in Melbourne http://archive.sciencewatch.com/ana/st/meta/11sepSTMetaZimm/


CONFERENCE ID: 898065#

USA:

Toll Free 1 855 881 1339


AUSTRALIA:
Toll Free `1800 558 698
Australian local number +61 2 9007 3187


UK: 0800 051 8245 .................... vin